Valuation: Aptevo Therapeutics Inc.

Market Cap 3.3M 2.97M 2.71M 2.48M 4.67M 310M 4.82M 32.69M 13.09M 166M 12.4M 12.14M 524M P/E 2026 *
-0.07x
P/E 2027 * -0.19x
Enterprise Value 3.3M 2.97M 2.71M 2.48M 4.67M 310M 4.82M 32.69M 13.09M 166M 12.4M 12.14M 524M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.85%
Yield 2026 *
-
Yield 2027 * -
10-26 Aptevo Therapeutics Inc. Reports Mipletamig Combination Therapy Enables 21% Of Frontline AML Patients To Advance To Potentially Curative Stem Cell Transplant CI
09-24 Aptevo Therapeutics Inc. Advances Next-Generation Trispecific Candidate Toward Clinical Development CI
08-14 Aptevo Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-27 Aptevo Therapeutics Inc. Announces New Solid Tumor Strategy and Filing of Patent Application Covering Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone CI
06-09 Aptevo Therapeutics Inc. And Niowave Inc. Join Forces To Advance Novel Targeted Cancer Therapeutics In The USD 17,000 million Oncology Category CI
05-28 Aptevo Therapeutics Inc. Appoints Mary J. Janatpour as Senior Vice President & Chief Scientific Officer CI
05-27 Aptevo Therapeutics Inc. And Niowave Inc. Launch Strategic Collaboration For Radiopharmaceutical Therapeutic Development CI
05-13 Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Aptevo Therapeutics Inc Reports Clinical Results and Provides Update on Rainier Frontline Acute Myeloid Leukemia Trial CI
03-27 Aptevo Therapeutics Inc. Shows 86% Clinical Benefit Rate For Mipletamig In Frontline AML CI
03-26 Aptevo Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-25 Aptevo Therapeutics Inc. Auditor Raises 'Going Concern' Doubt CI
03-11 Aptevo Therapeutics Inc Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine CI
Manager TitleAgeSince
Chief Executive Officer 61 2026-03-31
Director of Finance/CFO 60 2023-03-02
Chief Tech/Sci/R&D Officer 59 2026-05-27
Director TitleAgeSince
Chairman 64 2026-03-31
Director/Board Member 61 2026-03-31
Director/Board Member 71 2016-07-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/6/26 Exercice

Chief Technology Officer

1,432 0.1149%
8/6/26 Exercice

Director

800 0.0642%
8/6/26 Exercice

Chief Executive Officer

1,922 0.1542%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 3.3M
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average +0.28%+2.93%+56.16%+144.47% 40.58B
Weighted average by Cap. +0.21%+3.40%+53.12%+142.96%

Financials

2026 *2027 *
Net sales - -
Net income -26.82M -24.07M -21.99M -20.09M -37.88M -2.52B -39.07M -265M -106M -1.34B -101M -98.49M -4.25B -28.69M -25.75M -23.52M -21.49M -40.53M -2.69B -41.8M -284M -114M -1.44B -108M -105M -4.54B
Net Debt - -
Projected Income Statement - Annual - Aptevo Therapeutics Inc.
Logo Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Employees
33
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Aptevo Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.240USD
Average target price
25.50USD
Spread / Average Target
+1,956.45%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Aptevo Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. APVO Stock